Alexion Pharmaceuticals (ALXN) Lower As Biotechs See Pressure
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) is raising eyebrows today as shares are seeing notable weakness. The stock is down 3.6% mid-day although there is no news to explain the action.
ALXN is not the only large biotech seeing weakness, although it is under-performing the group. Biogen Idec (Nasdaq: BIIB) is down 2.8%, Gilead Sciences (Nasdaq: GILD) is down 2%, Amgen Inc. (Nasdaq: AMGN) is down 1.9%, Celgene Corporation (Nasdaq: CELG) is down 1.8%. Sector ETF iShares Nasdaq Biotechnology In (NYSE: IBB) is down 1.7%.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
ALXN is not the only large biotech seeing weakness, although it is under-performing the group. Biogen Idec (Nasdaq: BIIB) is down 2.8%, Gilead Sciences (Nasdaq: GILD) is down 2%, Amgen Inc. (Nasdaq: AMGN) is down 1.9%, Celgene Corporation (Nasdaq: CELG) is down 1.8%. Sector ETF iShares Nasdaq Biotechnology In (NYSE: IBB) is down 1.7%.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Maastricht Treaty to Blame for Crisis in EU...
- Spain's Bankia is Looking for 19 Billion Euro Infusion From the Spanish Government
- Faber - Greek Exit Good for Markets, India and China a Risk
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
